Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects


Sergentanis TN, Kastritis E, Terpos E, Dimopoulos MA, Psaltopoulou T. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. Clinical Lymphoma, Myeloma and Leukemia [Internet]. 2016;16(6):335 - 340.


Background A variety of clinical and laboratory prognostic factors for multiple myeloma (MM) have been addressed in published studies. The prognostic significance of cytogenetic abnormalities is also under investigation. Patients and Methods The present study evaluated the potential prognostic role of cytogenetic events and their combinations in terms of overall survival in a large cohort of unselected patients with MM (n = 432). Multivariate Cox regression analysis was performed, adjusting for age, gender, Chronic Kidney Disease Epidemiology Collaboration Kidney Disease: Improving Global Outcomes classification, International Staging System score, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase, serum calcium, platelet count, and blood hemoglobin. Results The presence of del(13q) (adjusted hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.18-2.47), t(4;14) (adjusted HR, 2.00; 95% CI, 1.19-3.35), and/or del(17p) (adjusted HR, 2.03; 95% CI, 1.22-3.37) was independently associated with poorer overall survival. The poor prognosis seemed more pronounced among patients harboring combinations of 2 adverse cytogenetic abnormalities. In contrast, t(14;16), t(11;14), and add(1q21) were not associated with overall survival. The effect of bortezomib seemed rather minimal in the modification of the prognostic role mediated by del(17p). Conclusion The presence of del(13q), t(4;14), and del(17p), singly or in combination, seems to be an independent poor prognostic factor for patients with MM. © 2016 Elsevier Inc.


Cited By :2Export Date: 18 February 2017References: Raab, M.S., Podar, K., Breitkreutz, I., Richardson, P.G., Anderson, K.C., Multiple myeloma (2009) Lancet, 374, pp. 324-339;Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group (2003) Br J Haematol, 121, pp. 749-757; Bondy, M., Ligon, B.L., Epidemiology and etiology of intracranial meningiomas: A review (1996) J Neurooncol, 29, pp. 197-205; Munshi, N.C., Plasma cell disorders: An historical perspective (2008) Hematology Am Soc Hematol Educ Program, p. 297; Sant, M., Minicozzi, P., Mounier, M., Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study (2014) Lancet Oncol, 15, pp. 931-942; Greipp, P.R., San Miguel, J., Durie, B.G., International staging system for multiple myeloma (2005) J Clin Oncol, 23, pp. 3412-3420; Ludwig, H., Durie, B.G., Bolejack, V., Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: An analysis of 10 549 patients from the International Myeloma Working Group (2008) Blood, 111, pp. 4039-4047; Dimopoulos, M.A., Kastritis, E., Delimpasi, S., Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era (2012) Eur J Haematol, 89, pp. 10-15; Terpos, E., Christoulas, D., Kastritis, E., The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; Is it time to change from MDRD to CKD-EPI-CysC equations? (2013) Eur J Haematol, 91, pp. 347-355; Terpos, E., Katodritou, E., Roussou, M., High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents (2010) Eur J Haematol, 85, pp. 114-119; Maillet, D., Montiel-Cervantes, L., Padilla-Gonzalez, Y., Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma (2012) Rev Invest Clin, 64, pp. 17-24; Perosa, F., Minoia, C., Favoino, E., Prete, M., Dammacco, F., Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class i heavy chain together with IgM or platelet count (2009) Blood Cells Mol Dis, 42, pp. 71-76; Mittelman, M., The implications of anemia in multiple myeloma (2003) Clin Lymphoma, 4, pp. S23-S29; Avet-Loiseau, H., Attal, M., Campion, L., Long-term analysis of the IFM 99 trials for myeloma: Cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival (2012) J Clin Oncol, 30, pp. 1949-1952; Paul, E., Sutlu, T., Deneberg, S., Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation (2009) Oncol Rep, 22, pp. 137-142; Boyd, K.D., Ross, F.M., Chiecchio, L., Gender disparities in the tumor genetics and clinical outcome of multiple myeloma (2011) Cancer Epidemiol Biomarkers Prev, 20, pp. 1703-1707; Jagannath, S., Richardson, P.G., Sonneveld, P., Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (2007) Leukemia, 21, pp. 151-157; Sagaster, V., Ludwig, H., Kaufmann, H., Bortezomib in relapsed multiple myeloma: Response rates and duration of response are independent of a chromosome 13q-deletion (2007) Leukemia, 21, pp. 164-168; Palumbo, A., Avet-Loiseau, H., Oliva, S., Revised International Staging System for multiple myeloma: A report from International Myeloma Working Group (2015) J Clin Oncol, 33, pp. 2863-2869; Ross, F.M., Avet-Loiseau, H., Ameye, G., Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders (2012) Haematologica, 97, pp. 1272-1277; Avet-Loiseau, H., Li, J.Y., Morineau, N., Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome (1999) Blood, 94, pp. 2583-2589; Lopez-Corral, L., Gutierrez, N.C., Vidriales, M.B., The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells (2011) Clin Cancer Res, 17, pp. 1692-1700; Chiecchio, L., Dagrada, G.P., Ibrahim, A.H., Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context (2009) Haematologica, 94, pp. 1708-1713; Fonseca, R., Bailey, R.J., Ahmann, G.J., Genomic abnormalities in monoclonal gammopathy of undetermined significance (2002) Blood, 100, pp. 1417-1424; Zojer, N., Konigsberg, R., Ackermann, J., Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization (2000) Blood, 95, pp. 1925-1930; Konigsberg, R., Zojer, N., Ackermann, J., Predictive role of interphase cytogenetics for survival of patients with multiple myeloma (2000) J Clin Oncol, 18, pp. 804-812; Oh, S., Koo, D.H., Kwon, M.J., Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: Web-based multicenter registry study (2014) Ann Hematol, 93, pp. 1353-1361; Fonseca, R., Oken, M.M., Harrington, D., Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy (2001) Leukemia, 15, pp. 981-986; Tricot, G., Sawyer, J.R., Jagannath, S., Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants (1997) J Clin Oncol, 15, pp. 2659-2666; Neemat, K., Rania, K., Tarek, M., Hamdy, A.A., Effect of 13q deletion on IL-6 production in patients with multiple myeloma: A hypothesis may hold true (2014) Clin Lab, 60, pp. 1393-1399; Avet-Loiseau, H., Attal, M., Moreau, P., Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome (2007) Blood, 109, pp. 3489-3495; Gutierrez, N.C., Castellanos, M.V., Martin, M.L., Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: T(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis (2007) Leukemia, 21, pp. 143-150; Kalff, A., Spencer, A., The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: Prognostic implications and current clinical strategies (2012) Blood Cancer J, 2, p. e89; Keats, J.J., Reiman, T., Maxwell, C.A., In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression (2003) Blood, 101, pp. 1520-1529; Avet-Loiseau, H., Leleu, X., Roussel, M., Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p) (2010) J Clin Oncol, 28, pp. 4630-4634; Fonseca, R., Blood, E., Rue, M., Clinical and biologic implications of recurrent genomic aberrations in myeloma (2003) Blood, 101, pp. 4569-4575; Reece, D., Song, K.W., Fu, T., Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: Adverse effect of deletion 17p13 (2009) Blood, 114, pp. 522-525; Chang, H., Qi, C., Yi, Q.L., Reece, D., Stewart, A.K., P53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation (2005) Blood, 105, pp. 358-360; Drach, J., Ackermann, J., Fritz, E., Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy (1998) Blood, 92, pp. 802-809; Prideaux, S.M., Conway O'Brien, E., Chevassut, T.J., The genetic architecture of multiple myeloma (2014) Adv Hematol, 2014, p. 864058; Chang, H., Qi, X., Jiang, A., Xu, W., Young, T., Reece, D., 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma (2010) Bone Marrow Transplant, 45, pp. 117-121; Avet-Loiseau, H., Malard, F., Campion, L., Translocation t(14;16) and multiple myeloma: Is it really an independent prognostic factor? (2011) Blood, 117, pp. 2009-2011